<DOC>
	<DOCNO>NCT01591850</DOCNO>
	<brief_summary>This randomize , single-center , open-label , one-sequence , two-period crossover study three part assess effect multiple dos ketoconazole , rifampicin ritonavir-boosted atazanavir pharmacokinetics single dose RO5093151 healthy male female volunteer . In Period 1 , subject receive single oral dose RO5093151 . In Period 2 , subject receive single oral dose RO5093151 multiple oral dos either ketoconazole , rifampicin ritonavir-boosted atazanavir . Anticipated time study 8.5 week .</brief_summary>
	<brief_title>A Drug-Drug Interaction Study Ketoconazole , Rifampicin Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy male female subject , 18 65 year age . Healthy status define absence evidence active chronic disease follow detailed medical surgical history complete physical examination Body mass index ( BMI ) 18 30 kg/m2 Females childbearing potential must agree use two effective method contraception , include barrier method intrauterine nonhormonal device ( set place least 3 month first dose ) duration study least 1 month last dosing Nonsmoker least 90 day prior screen Pregnant lactate female History drug abuse past 2 year , suspicion regular consumption drug abuse , positive result drug abuse test History alcoholism past 2 year , positive alcohol test Positive hepatitis B , hepatitis C HIV infection Systemic , topical , intranasal inhale corticosteroid therapy 2 week within 3 month prior screen Participation investigational drug device study within 90 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>